Working in an unparalleled environment, our center’s investigators conduct a broad array of interdisciplinary research in translational cardiovascular medicine.
We strive to develop novel approaches to improve heart function and to study the efficacy of therapeutic interventions in preclinical models that reproduce human ischemic heart disease and heart failure. Data from these investigations help advance therapies to early-phase clinical trials.
Our preclinical research focuses on:
We use molecular imaging and high-throughput molecular biology to understand molecular pathophysiology.
We conduct clinical investigations to evaluate therapies for patients with heart failure, ischemia and arrhythmia.
Our faculty participate in, and lead, major multicenter trials in addition to initiating single-center, patient-oriented investigations.
We receive funding from:
We’re located in the UB Clinical and Translational Center (CTRC), directly above the Gates Vascular Institute. This proximity allows us to conduct bench-to-bedside research within steps of our division’s primary site for patient care, where we pursue novel surgical therapeutics.
Additionally, the apposition of medical care and research facilities allows our investigators to collaborate across the translational interface.
As the hub for our medical school’s $15 million Clinical and Translational Sciences Award from the National Institutes of Health, the CTRC links our researchers with other scientists in the Buffalo Translational Consortium. We take full advantage of the CTRC’s resources, including the Translational Imaging Center and the Clinical Research Center.